1988 Volume 79 Issue 4 Pages 732-737
Four patients with advanced testicular cancer which had been refractory to prior BVP therapy were treated with combination chemotherapy containing CDDP and VP-16 (salvage chemotherapy). Following the high dose salvage therapy using 100mg/sq. m CDDP and 500mg/sq. m VP-16 devided in 5-fractioned dose either with or without belomycin, two patients achieved complete remission (CR) and remained disease free for more than 4 months, though bone marrow suppression was remarkable. Two patients treated with low dose therapy failed to be salvaged.
Therefore, it was concluded that salvage chemotherapy should be given at high dose. However, because of increased myelosuppresion following salvage chemotherapy in patients with prior treatment, salvage regimen (PEB) should be, ab initio, given to patients with far advanced testicular cancer.
